HK1126480A1 - 3, 7-diamino-10h-phenothiazine salts and their use - Google Patents

3, 7-diamino-10h-phenothiazine salts and their use

Info

Publication number
HK1126480A1
HK1126480A1 HK09105064.1A HK09105064A HK1126480A1 HK 1126480 A1 HK1126480 A1 HK 1126480A1 HK 09105064 A HK09105064 A HK 09105064A HK 1126480 A1 HK1126480 A1 HK 1126480A1
Authority
HK
Hong Kong
Prior art keywords
4alkyl
4alkenyl
halogenated
independently selected
diamino
Prior art date
Application number
HK09105064.1A
Other languages
English (en)
Inventor
Claude Michel Wischik
Janet Elizabeth Rickard
Charles Robert Harrington
David Horsley
John Mervyn David Storey
Colin Marshall
James Peter Sinclair
Thomas Craven Baddeley
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38421429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1126480(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of HK1126480A1 publication Critical patent/HK1126480A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
HK09105064.1A 2006-03-29 2009-06-05 3, 7-diamino-10h-phenothiazine salts and their use HK1126480A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78669006P 2006-03-29 2006-03-29
PCT/GB2007/001103 WO2007110627A2 (fr) 2006-03-29 2007-03-28 Sels de 3,7-diamino-10h-phénothiazine et utilisation correspondante

Publications (1)

Publication Number Publication Date
HK1126480A1 true HK1126480A1 (en) 2009-09-04

Family

ID=38421429

Family Applications (4)

Application Number Title Priority Date Filing Date
HK09105064.1A HK1126480A1 (en) 2006-03-29 2009-06-05 3, 7-diamino-10h-phenothiazine salts and their use
HK14112923.1A HK1199444A1 (en) 2006-03-29 2014-12-24 Method of preparing 3,7-diamino-10h-phenothiazine compounds 3,7--10h-
HK15109987.9A HK1209417A1 (en) 2006-03-29 2015-10-13 3,7-diamino-10h-phenothiazine salts and their use 37--10h-
HK15110959.1A HK1210047A1 (en) 2006-03-29 2015-11-06 3,7-diamino-10h-phenothiazine salts and their use 37--10h-

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK14112923.1A HK1199444A1 (en) 2006-03-29 2014-12-24 Method of preparing 3,7-diamino-10h-phenothiazine compounds 3,7--10h-
HK15109987.9A HK1209417A1 (en) 2006-03-29 2015-10-13 3,7-diamino-10h-phenothiazine salts and their use 37--10h-
HK15110959.1A HK1210047A1 (en) 2006-03-29 2015-11-06 3,7-diamino-10h-phenothiazine salts and their use 37--10h-

Country Status (19)

Country Link
US (3) US7888350B2 (fr)
EP (1) EP2013191B3 (fr)
JP (3) JP5520043B2 (fr)
KR (1) KR100983301B1 (fr)
CN (5) CN109384741B (fr)
AT (1) ATE478058T3 (fr)
AU (1) AU2007231124B2 (fr)
CA (1) CA2646163C (fr)
DE (1) DE602007008550D1 (fr)
DK (1) DK2013191T6 (fr)
EA (1) EA014552B1 (fr)
ES (1) ES2349322T7 (fr)
HK (4) HK1126480A1 (fr)
HR (1) HRP20100614T4 (fr)
IL (2) IL194516A (fr)
MY (1) MY143757A (fr)
PL (1) PL2013191T6 (fr)
PT (1) PT2013191E (fr)
WO (1) WO2007110627A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084204B (zh) 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
EP2013191B3 (fr) * 2006-03-29 2019-02-27 Wista Laboratories Ltd. Sels de 3,7-diamino-10h-phenothiazine et utilisation correspondante
PT2004155T (pt) 2006-03-29 2018-05-02 Wista Lab Ltd Inibidores de agregação proteica
HUE030621T2 (en) 2006-07-11 2017-05-29 Wista Lab Ltd Methods for the synthesis and / or purification of diaminophenothiazinium compounds
AU2008237276A1 (en) * 2007-04-03 2008-10-16 Prosetta Bioconformatics, Inc. Phenothiazin derivatives for antiviral treatments
CN101820884B (zh) * 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
FR2920775B1 (fr) * 2007-09-07 2009-11-06 Pharma Hydro Dev P H D Soc Par Nouveaux composes diaminophenothiazine, leur procede de preparation et leurs utilisations.
SI2205245T1 (sl) * 2007-10-03 2015-10-30 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov
ES2600278T3 (es) 2008-12-10 2017-02-08 Wista Laboratories Ltd. Sales de xantilio 3,6-disustituidas como medicamentos
WO2011036558A2 (fr) * 2009-09-24 2011-03-31 Wista Laboratories Ltd. Chlorhydrates de méthylthioninium cristallins
PT2480540T (pt) * 2009-09-24 2018-02-16 Wista Lab Ltd Pentahidrato de cloreto de metiltionínio e respetivas preparação e utilização farmacêutica
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
EP2645994B1 (fr) 2010-11-30 2017-11-01 WisTa Laboratories Ltd. Formulations comprenant le chlorure de methylthioninium
CA2826286C (fr) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Traitement de tauopathies
US9283230B2 (en) 2011-02-11 2016-03-15 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
ITUA20163526A1 (it) * 2016-05-17 2017-11-17 Icrom Spa Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza
EP4223297A3 (fr) 2016-07-25 2023-11-15 WisTa Laboratories Ltd. Administration et dosage de diaminophénothiazines
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) * 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
CN107253936B (zh) * 2017-06-23 2021-07-23 复旦大学 一类可用于次氯酸检测的荧光探针及其制备方法和应用
CN108129418A (zh) * 2017-12-22 2018-06-08 郑州大学 吩噻嗪-氨基二硫代甲酸酯衍生物及其制备方法和应用
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
CN112955972A (zh) 2018-09-05 2021-06-11 云顶道卫思诊断中心有限公司 神经系统变性疾病的网络方法
CN109223800A (zh) * 2018-10-26 2019-01-18 辽宁大学 3,7-二对甲苯胺基-吩噻嗪-5-鎓碘化物与超声协同在抑制肿瘤细胞增殖中的应用
CN113874078A (zh) 2019-04-05 2021-12-31 Tauc3生物制品有限公司 抗tauc3抗体及其应用
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
JP2023525512A (ja) 2020-05-05 2023-06-16 ウィスタ ラボラトリーズ リミテッド Ｃｏｖｉｄ－１９の治療で使用されるメチルチオニニウム化合物
JP2023524146A (ja) 2020-05-05 2023-06-08 ウィスタ ラボラトリーズ リミテッド 低酸素血症の治療に使用されるメチルチオニニウム化合物
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
DE102020212508A1 (de) 2020-10-02 2022-04-07 Continental Reifen Deutschland Gmbh Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Antiozonant und/oder Farbstoff
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment
WO2023232764A1 (fr) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Traitement de troubles neurodégénératifs à l'aide de composés contenant du méthylthioninium (mt)
WO2024063700A1 (fr) 2022-09-21 2024-03-28 Yin Sze Loh Formulation orale de diaminophénothiazines et procédés de fabrication et d'utilisation de celle-ci dans le traitement et/ou la prévention de maladies

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (fr) * 1957-07-17
US3641016A (en) * 1968-02-16 1972-02-08 Egyt Gyogyszervegyeszeti Gyar Thionine derivatives
JPS52105931A (en) * 1976-03-02 1977-09-06 Mita Industrial Co Ltd New leuco coloring matters and process for manufacture thereof
US4309255A (en) 1980-09-10 1982-01-05 International Business Machines Corporation Electrochromic recording paper
US4647525A (en) * 1984-10-01 1987-03-03 Minnesota Mining And Manufacturing Company Stabilized leuco phenazine dyes and their use in an imaging system
US4622395A (en) * 1984-10-01 1986-11-11 Minnesota Mining And Manufacturing Company Phenoxazine and phenothiazine dyes and leuco forms thereof
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
US5571666A (en) * 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
CA2011116C (fr) * 1989-03-06 1999-11-16 Murray A. Kaplan Dihydrochlorure de bmy-28142 lyophilise pour usage parenteral
US5220009A (en) 1990-05-03 1993-06-15 Yeda Research And Development Company Limited Phenothiazinium salts and their use for disinfecting aqueous effluents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1993003177A1 (fr) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Nouvelles proteines kinases a neurofilament et tau
DE4140192C2 (de) 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
ES2136654T3 (es) 1991-12-06 1999-12-01 Max Planck Gesellschaft Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer.
JPH06289015A (ja) 1993-03-30 1994-10-18 Sunstar Inc フェノチアジン系色源体安定化組成物
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
AU708682B2 (en) 1994-08-08 1999-08-12 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) * 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
CA2278245A1 (fr) 1997-01-21 1998-07-23 The American National Red Cross Decontamination intracellulaire et extracellulaire de sang total et de composants du sang au moyen de colorants amphiphiles phenotiazin-5-ium et de lumiere
WO1999062548A1 (fr) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Procedes et compositions pour le diagnostic des pathologies tau
FR2788436A1 (fr) 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
WO2001053340A2 (fr) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Modele murin transgenique de maladies neurodegeneratives humaines
GB0017060D0 (en) 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2003000714A2 (fr) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions et procedes pour la prevention d'agregation de proteines dans des maladies neurodegeneratives
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
AU2004295148A1 (en) 2003-11-28 2005-06-16 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
EP3564223A1 (fr) 2004-09-23 2019-11-06 WisTa Laboratories Ltd. Procédés de synthèse chimique et de purification de composés de diaminophénothiazinium contenant du chlorure de méthylthioninium (mtc)
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
EP2013191B3 (fr) * 2006-03-29 2019-02-27 Wista Laboratories Ltd. Sels de 3,7-diamino-10h-phenothiazine et utilisation correspondante
PT2004155T (pt) 2006-03-29 2018-05-02 Wista Lab Ltd Inibidores de agregação proteica
HUE030621T2 (en) 2006-07-11 2017-05-29 Wista Lab Ltd Methods for the synthesis and / or purification of diaminophenothiazinium compounds
CN101820884B (zh) 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
SI2205245T1 (sl) 2007-10-03 2015-10-30 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov
US9283230B2 (en) 2011-02-11 2016-03-15 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use

Also Published As

Publication number Publication date
HRP20100614T4 (hr) 2019-08-09
AU2007231124A1 (en) 2007-10-04
US11951110B2 (en) 2024-04-09
DK2013191T6 (en) 2019-04-23
EP2013191A2 (fr) 2009-01-14
HK1199444A1 (en) 2015-07-03
KR20080110879A (ko) 2008-12-19
IL194516A (en) 2015-02-26
CN101460472B (zh) 2015-06-17
ATE478058T3 (de) 2010-09-15
EA014552B1 (ru) 2010-12-30
CN109384741B (zh) 2023-01-06
JP2009531403A (ja) 2009-09-03
IL231890A0 (en) 2014-05-28
US20160051559A1 (en) 2016-02-25
CA2646163A1 (fr) 2007-10-04
PL2013191T6 (pl) 2019-07-31
HK1210047A1 (en) 2016-04-15
AU2007231124B2 (en) 2013-02-21
HK1209417A1 (en) 2016-04-01
PT2013191E (pt) 2010-10-29
ES2349322T3 (es) 2010-12-29
US20090054419A1 (en) 2009-02-26
US11344558B2 (en) 2022-05-31
PL2013191T3 (pl) 2011-02-28
JP2014055165A (ja) 2014-03-27
CN104529939A (zh) 2015-04-22
CN104606199A (zh) 2015-05-13
EA200870384A1 (ru) 2009-04-28
CN104119294B (zh) 2018-10-30
MY143757A (en) 2011-07-15
ES2349322T7 (es) 2019-10-17
CN104119294A (zh) 2014-10-29
JP5814957B2 (ja) 2015-11-17
IL194516A0 (en) 2009-08-03
US7888350B2 (en) 2011-02-15
JP5520043B2 (ja) 2014-06-11
US20220152038A1 (en) 2022-05-19
EP2013191B3 (fr) 2019-02-27
DE602007008550D1 (de) 2010-09-30
WO2007110627A3 (fr) 2007-11-22
CA2646163F (fr) 2007-10-04
CN104529939B (zh) 2019-05-07
JP2013121985A (ja) 2013-06-20
WO2007110627A2 (fr) 2007-10-04
CN104606199B (zh) 2022-09-13
CN109384741A (zh) 2019-02-26
IL231890A (en) 2016-10-31
CA2646163C (fr) 2011-03-15
EP2013191B1 (fr) 2010-08-18
DK2013191T3 (da) 2010-11-22
HRP20100614T1 (en) 2010-12-31
CN101460472A (zh) 2009-06-17
KR100983301B1 (ko) 2010-09-20

Similar Documents

Publication Publication Date Title
HK1210047A1 (en) 3,7-diamino-10h-phenothiazine salts and their use 37--10h-
MY139446A (en) Novel quinoline derivatives
TW200728307A (en) Novel spirochromanone derivatives
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
PL2018379T3 (pl) Sole skopiny oraz ich zastosowanie w sposobach wytwarzania N-demetylo-tiotropium i bromku tiotropium
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
RS28004A (en) Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
IL217446A (en) Pharmaceutical preparation containing a highly purified active ingredient of 7 - chloro - 5 - hydroxy - 1 - [2 - methyl - 4 - (2 - methylbenzoyl - amino) benzoyl] - 2, 3, 4, 5 - tetrahydro - h - 1 - Benzazepine has a purity of more than 99.5% or its salt, or a drug of its salt
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
SG161217A1 (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
PL2229938T3 (pl) Kompozycje ezetymibu
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
TW200606164A (en) New compounds
AP1522A (en) Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them.
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
TW200704633A (en) Process for the preparation of sulfonamide derivatives
TW200800984A (en) New compounds
WO2007075838A3 (fr) Bromure de tiotropium pur et stable
WO2003074529A3 (fr) Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
WO2005033279A3 (fr) Decouverte de nouveaux anesthesiques solubles cristallins
RS20050954A (en) Use of bycyclo/2.2.1/heptane derivatives for the preparation of neuroprotective pharmaceutical compositions

Legal Events

Date Code Title Description
AM46 Amendment of patent specifications after grant under section 46 of the patents ordinance